Core Viewpoint - David Medical (300314.SZ) has received a Class I medical device registration number notification from the Ningbo Market Supervision Administration for its ECG lead wires [1] Company Summary - The product involved in the notification is ECG lead wires, which are essential components in cardiac monitoring and diagnostics [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-051 宁波戴维医疗器械股份有限公司 关于获得第一类医疗器械备案凭证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、情况概述 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日收到 宁波市市场监督管理局核发的1项《第一类医疗器械备案编号告知书》， 具体情况如下： | 产品名称 | 心电导联线 | | --- | --- | | 备案编号 | 浙甬械备20250277 | | 备案人名称 | 宁波戴维医疗器械股份有限公司 | | 备案人统一社会信 | 91330200610257495J | | 用代码 | | | 备案人住所 | 浙江省宁波市象山县石浦科技园区科苑路2号 | | 生产地址 | 浙江省宁波市象山县石浦科技园区科苑路2号 | | | DL-05-010、DL-03-020（A）、DL-03-020（B）、DL-05-020 | | | （A）、DL-05-020（B）、DL-05-110、DL-03-120（A）、 | | 型号/规格 | DL-03-120（B）、DL ...

Core Insights - David Medical announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a portable electronic endoscope image processor [1] Group 1 - The product is a portable electronic endoscope image processor [1]

Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]

Group 1 - David Medical (SZ 300314) announced on October 13 that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a "Portable Electronic Endoscope Image Processor" [1] - For the fiscal year 2024, David Medical's revenue composition is projected to be 98.08% from the medical device manufacturing sector and 1.92% from other businesses [1] - The current market capitalization of David Medical is 3.9 billion yuan [2]

Core Insights - David Medical (300314.SZ) announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a portable electronic endoscope image processor [1] Group 1 - The registered product is a portable electronic endoscope image processor designed to be used with disposable electronic endoscopes [1] - The device features a built-in high-definition display and internal power supply, enabling it to meet various usage scenarios [1] - The high-quality imaging capabilities enhance the disposable electronic endoscope products, allowing doctors to clearly capture fine structures and diseased tissues during surgeries [1]

Core Viewpoint - David Medical (300314.SZ) announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., has recently received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a portable electronic endoscope image processor [1] Group 1 - The product is named "Portable Electronic Endoscope Image Processor" [1]

Core Viewpoint - David Medical (300314.SZ) announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd. (referred to as "Weierkaidi"), has recently received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a portable electronic endoscope image processor [1] Group 1 - The product is a portable electronic endoscope image processor [1] - The registration certificate was issued by the Zhejiang Provincial Drug Administration [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-050 宁波戴维医疗器械股份有限公司 关于全资子公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日收到浙江 省药品监督管理局颁发的1项《医疗器械注册证》，具体如下： 一、医疗器械注册证的具体情况 目前尚无法预测该等产品对公司未来营业收入的影响，敬请投资者注 意投资风险。 特此公告。 适用范围：该产品与本公司生产的电子内窥镜配套使用，用于在内窥 镜诊断和/或治疗手术中与电子内窥镜连接，有效地在监视器上显示内窥镜 观察人体体腔的视场区域的图像。 二、新产品的市场状况 维尔凯迪本次获注册的便携式电子内窥镜图像处理器配套一次性电子 内窥镜使用，自带高清显示器并内置电源可以满足更多使用场景，优质的 产品名称：便携式电子内窥镜图像处理器 型号、规格：DW-M12 注册证编号：浙械注准20252061785 批准日期：2025年10月12日 有效期至：2030年1 ...

（文章来源：证券日报） 证券日报网讯戴维医疗9月29日在互动平台回答投资者提问时表示，截至2025年9月19日，公司股东总户 数约为20800户。 ...